Claims for Patent: 10,245,348

Summary for Patent: 10,245,348

Title:	Process for making dry and stable hemostatic compositions
Abstract:	Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) providing said first component and said second component in a combined form in a final container, c1) either by filling said first component and said second component into said final container so as to obtain a dry mixture in said final container, c2) or by providing said first component or said second component in said final container and adding said second component or said first component so as to obtain a combination of said first component with said second component in said final container, d) finishing the final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.
Inventor(s):	Goessl; Andreas (Vienna, AT), Osawa; Atsushi Edward (San Francisco, CA), Reich; Cary J. (Los Gatos, CA)
Assignee:	Baxter International Inc. (Deerfield, IL) Baxter Healthcare SA (Glattpark (Opfikon), CH)
Application Number:	14/804,084
Patent Claims:	1. A process for making a dry and stable hemostatic composition, the process comprising: lyophilizing an aqueous preparation of thrombin in a container so as to provide a first component in the container, the first component comprising a dry preparation of thrombin; compacting the first component in the container following the lyophilizing step; adding a second component to the container following the lyophilizing step, the second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis; mixing the first component and the second component, so as to obtain a dry mixture of the first component with the second component in the container; and finishing the container to a storable pharmaceutical device containing the first component and the second component in a combined form as a dry and stable hemostatic composition. 2. The process according to claim 1, wherein the container comprises a member selected from the group consisting of a syringe, a vial, and a tube. 3. The process according to claim 1, wherein the adding step is performed under aseptic conditions. 4. The process according to claim 1, wherein the finishing step comprises an ethylene oxide sterilization step or a treatment with ionizing irradiation. 5. The process according to claim 1, wherein the container is a container finished together with a diluent container with a pharmaceutically acceptable diluent for reconstituting the dry and stable hemostatic composition. 6. The process according to claim 1, wherein the thrombin is human thrombin. 7. The process according to claim 1, wherein the thrombin is recombinant human thrombin. 8. The process according to claim 1, wherein the thrombin is bovine thrombin. 9. The process according to claim 1, wherein the biocompatible polymer suitable for use in hemostasis contains a protein selected from the group consisting of gelatin, soluble collagen, albumin, hemoglobin, fibrinogen, fibrin, casein, fibronectin, elastin, keratin, laminin, and derivatives or combinations thereof. 10. The process according to claim 1, wherein the biocompatible polymer suitable for use in hemostasis contains a polysaccharide selected from the group consisting of glycosaminoglycans, starch derivatives, cellulose derivatives, hemicellulose derivatives, xylan, agarose, alginate, chitosan, and derivatives or combinations thereof. 11. The process according to claim 1, wherein the biocompatible polymer suitable for use in hemostasis contains a polymer selected from the group consisting of polyacrylates, polymethacrylates, polyacrylamides, polyvinyl resins, polylactide-glycolides, polcaprolactones, polyoxyethlenes, and derivatives and combinations thereof. 12. The process according to claim 1, wherein the biocompatible polymer suitable for use in hemostasis contains a member selected from the group consisting of a crosslinked polysaccharide, a crosslinked protein, a crosslinked non-biologic polymer, and mixtures thereof. 13. The process according to claim 1, wherein the biocompatible polymer suitable for use in hemostasis is a particulate material. 14. The process according to claim 1, wherein the biocompatible polymer suitable for use in hemostasis is a cross-linked gelatin. 15. The process according to claim 1, wherein the container further contains an amount of a stabilizer effective to inhibit modification of the polymer when exposed to the sterilizing radiation, and wherein the stabilizer is selected from the group consisting of ascorbic acid, sodium ascorbate, other salts of ascorbic acid, and an antioxidant. 16. A method for delivering a hemostatic composition to a target site in a patient's body, the method comprising delivering a hemostatic composition produced by the process of claim 1 to the target site. 17. A method according to claim 16 further comprising the step of contacting the hemostatic composition with a pharmaceutically acceptable diluent so as to obtain a hemostatic composition in a hydrogel form. 18. The process according to claim 1, wherein the dry preparation of the biocompatible polymer is in granular form, and the step of adding the second component to the container comprises filling the dry preparation of the biocompatible polymer on top of the first component. 19. The process according to claim 1, wherein compacting the first component in the container comprises compacting under vacuum. 20. The process according to claim 1, wherein the step of adding the second component to the container comprises filling the dry preparation of the biocompatible polymer on top of the compacted first component. 21. The process according to claim 1, further comprising compacting the second component in the container following the adding step. 22. The process according to claim 1, wherein the container is one syringe.

Details for Patent 10,245,348

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Omrix Biopharmaceuticals Ltd	EVITHROM	thrombin, topical (human)	Solution	125247	August 27, 2007		2030-06-01
Omrix Biopharmaceuticals Ltd	EVITHROM	thrombin, topical (human)	For Injection	125247	September 17, 2009		2030-06-01